USANA Health Sciences (NYSE:USNA) Shares Pass Above 200-Day Moving Average of $57.02

USANA Health Sciences logoUSANA Health Sciences, Inc. (NYSE:USNA – Get Rating) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $57.02 and trades as high as $62.44. USANA Health Sciences shares last traded at $61.70, with a volume of 66,277 shares.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on USNA. DA Davidson upped their price target on shares of USANA Health Sciences from $49.00 to $52.50 and gave the stock a “neutral” rating in a report on Monday, February 13th. StockNews.com upgraded shares of USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Friday, March 10th.

USANA Health Sciences Stock Performance

The company’s fifty day simple moving average is $59.74 and its 200-day simple moving average is $57.02. The company has a market capitalization of $1.19 billion, a P/E ratio of 17.19 and a beta of 0.74.

Want More Great Investment Ideas?

USANA Health Sciences (NYSE:USNA – Get Rating) last issued its earnings results on Tuesday, February 7th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.31. The company had revenue of $227.96 million for the quarter. USANA Health Sciences had a net margin of 6.94% and a return on equity of 16.92%. During the same quarter in the previous year, the company earned $1.03 earnings per share. On average, sell-side analysts predict that USANA Health Sciences, Inc. will post 2.85 EPS for the current year.

Insider Buying and Selling at USANA Health Sciences

In other USANA Health Sciences news, CEO Kevin Guest sold 13,288 shares of the stock in a transaction dated Wednesday, February 22nd. The shares were sold at an average price of $60.28, for a total transaction of $801,000.64. Following the completion of the sale, the chief executive officer now directly owns 9,355 shares of the company’s stock, valued at $563,919.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, insider Brent Neidig sold 1,872 shares of the stock in a transaction that occurred on Thursday, February 9th. The shares were sold at an average price of $61.89, for a total value of $115,858.08. Following the completion of the transaction, the insider now directly owns 2,435 shares of the company’s stock, valued at approximately $150,702.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible via the SEC website. Also, CEO Kevin Guest sold 13,288 shares of the firm’s stock in a transaction that occurred on Wednesday, February 22nd. The stock was sold at an average price of $60.28, for a total transaction of $801,000.64. Following the transaction, the chief executive officer now directly owns 9,355 shares of the company’s stock, valued at $563,919.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 24,632 shares of company stock valued at $1,490,529. 0.36% of the stock is currently owned by insiders.

Hedge Funds Weigh In On USANA Health Sciences

A number of institutional investors have recently bought and sold shares of USNA. Teacher Retirement System of Texas acquired a new stake in shares of USANA Health Sciences during the 3rd quarter worth approximately $637,000. Martingale Asset Management LP grew its stake in shares of USANA Health Sciences by 6.4% during the 2nd quarter. Martingale Asset Management LP now owns 13,392 shares of the company’s stock worth $970,000 after purchasing an additional 807 shares during the period. Cubist Systematic Strategies LLC grew its stake in shares of USANA Health Sciences by 10.6% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 20,291 shares of the company’s stock worth $1,137,000 after purchasing an additional 1,946 shares during the period. Summit Global Investments grew its stake in shares of USANA Health Sciences by 37.6% during the 3rd quarter. Summit Global Investments now owns 28,763 shares of the company’s stock worth $1,612,000 after purchasing an additional 7,856 shares during the period. Finally, Caxton Associates LP grew its stake in USANA Health Sciences by 372.6% in the 2nd quarter. Caxton Associates LP now owns 14,159 shares of the company’s stock valued at $1,025,000 after acquiring an additional 11,163 shares during the period. 52.62% of the stock is owned by hedge funds and other institutional investors.

USANA Health Sciences Company Profile

(Get Rating)

USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. It operates under the following segments: USANA Nutritionals, USANA Foods, Personal Care and Skincare, and All Other. The firm’s brands include Procosa and MagneCal D. The company was founded by Myron W.

Featured Articles

Receive News & Ratings for USANA Health Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for USANA Health Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.

Similar Posts